Rec 15/2615 dihydrochlorideCAS# 173059-17-1 |
- Safinamide Mesylate
Catalog No.:BCC2320
CAS No.:202825-46-5
- Moclobemide (Ro 111163)
Catalog No.:BCC2322
CAS No.:71320-77-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 173059-17-1 | SDF | Download SDF |
PubChem ID | 56972225 | Appearance | Powder |
Formula | C26H35Cl2N5O5 | M.Wt | 568.49 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-(2-methoxy-6-propan-2-ylphenoxy)ethanone;dihydrochloride | ||
SMILES | CC(C)C1=C(C(=CC=C1)OC)OCC(=O)N2CCN(CC2)C3=NC4=CC(=C(C=C4C(=N3)N)OC)OC.Cl.Cl | ||
Standard InChIKey | XZGSTPYGKYGQLD-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C26H33N5O5.2ClH/c1-16(2)17-7-6-8-20(33-3)24(17)36-15-23(32)30-9-11-31(12-10-30)26-28-19-14-22(35-5)21(34-4)13-18(19)25(27)29-26;;/h6-8,13-14,16H,9-12,15H2,1-5H3,(H2,27,28,29);2*1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective α1B-adrenoceptor antagonist (Ki values are 0.3, 1.9 and 2.6 nM at human α1B, α1A and α1D receptors respectively). |
Rec 15/2615 dihydrochloride Dilution Calculator
Rec 15/2615 dihydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.759 mL | 8.7952 mL | 17.5905 mL | 35.1809 mL | 43.9761 mL |
5 mM | 0.3518 mL | 1.759 mL | 3.5181 mL | 7.0362 mL | 8.7952 mL |
10 mM | 0.1759 mL | 0.8795 mL | 1.759 mL | 3.5181 mL | 4.3976 mL |
50 mM | 0.0352 mL | 0.1759 mL | 0.3518 mL | 0.7036 mL | 0.8795 mL |
100 mM | 0.0176 mL | 0.088 mL | 0.1759 mL | 0.3518 mL | 0.4398 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- PMPA (NAALADase inhibitor)
Catalog No.:BCC2354
CAS No.:173039-10-6
- Goniothalamin
Catalog No.:BCN4690
CAS No.:17303-67-2
- Poloxime
Catalog No.:BCC5307
CAS No.:17302-61-3
- Isoanthricin
Catalog No.:BCN3531
CAS No.:17301-70-5
- BWX 46
Catalog No.:BCC5865
CAS No.:172997-92-1
- Biorobin
Catalog No.:BCN4691
CAS No.:17297-56-2
- FICZ
Catalog No.:BCC5513
CAS No.:172922-91-7
- PB 28 dihydrochloride
Catalog No.:BCC7411
CAS No.:172907-03-8
- Isosinensetin
Catalog No.:BCN2919
CAS No.:17290-70-9
- LY 266097 hydrochloride
Catalog No.:BCC7856
CAS No.:172895-39-5
- LY 272015 hydrochloride
Catalog No.:BCC7558
CAS No.:172895-15-7
- PP 2 (AG 1879)
Catalog No.:BCC3631
CAS No.:172889-27-9
- Rhoifolin
Catalog No.:BCN1112
CAS No.:17306-46-6
- Ganoderic acid DM
Catalog No.:BCN1113
CAS No.:173075-45-1
- Centaureidin
Catalog No.:BCN2575
CAS No.:17313-52-9
- SQ 22536
Catalog No.:BCC7065
CAS No.:17318-31-9
- 4-Beta-Hydroxycholesterol
Catalog No.:BCN2752
CAS No.:17320-10-4
- Clomipramine HCl
Catalog No.:BCC5036
CAS No.:17321-77-6
- Broussonetine A
Catalog No.:BCN2515
CAS No.:173220-07-0
- 2,5-Dihydroxy-1-methoxyxanthone
Catalog No.:BCN7577
CAS No.:173220-32-1
- TC-E 5003
Catalog No.:BCC8008
CAS No.:17328-16-4
- Garciniaxanthone E
Catalog No.:BCN1114
CAS No.:173294-74-1
- Isorhamnetin 3-glucoside-7-rhamnoside
Catalog No.:BCN1528
CAS No.:17331-71-4
- Aliskiren
Catalog No.:BCC1338
CAS No.:173334-57-1
Alpha(1A)-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries.[Pubmed:17115072]
Br J Pharmacol. 2007 Jan;150(1):112-20.
BACKGROUND AND PURPOSE: Maintained penile erection depends on the absence of alpha-adrenoceptor (alpha-AR) activation and so can be facilitated by alpha-blockers. This study seeks the alpha(1)-AR subtypes involved in order to inform the pro-erectile consequences of subtype selective blockade. EXPERIMENTAL APPROACH: Wire myography was used with dorsal (nutritional supply) and cavernous (erectile inflow) penile arteries; standard alpha-AR-selective agonists and antagonists were employed to classify responses. KEY RESULTS: In both penile arteries noradrenaline (NA) and phenylephrine (PE, alpha(1)-AR agonist) caused concentration-dependent contractions. Sensitivity to NA was increased by NA uptake blockers, cocaine (3 microM) and corticosterone (30 microM). PE responses were antagonised by phentolamine (non-selective alpha-AR: dorsal pK(B) 8.00, cavernous 8.33), prazosin (non-subtype-selective alpha(1)-AR: dorsal 8.60, cavernous 8.41) and RS100329 (alpha(1A)-AR selective: dorsal 9.03, cavernous 8.80) but not by BMY7378 (alpha(1D)-AR selective: no effect at 1-100 nM) or Rec15/2615 (alpha(1B)-AR selective: no effect at 1-100 nM). Schild analysis was straightforward in cavernous artery, indicating that PE activates only alpha(1A)-AR. In dorsal artery Schild slopes were low, though alpha(1A)-AR was still indicated. Analysis using UK 14,304 and rauwolscine indicated an alpha(2)-AR component in dorsal artery that may account for low slopes to alpha(1)-AR antagonists. CONCLUSIONS AND IMPLICATIONS: Penile arteries have a predominant, functional alpha(1A)-AR population with little evidence of other alpha(1)-AR subtypes. Dorsal arteries (nutritional supply) also have alpha(2)-ARs. Thus, alpha-AR blockers with affinity for alpha(1A)-AR or alpha(2)-AR would potentially have pro-erectile properties; the combination of these perhaps being most effective. This should inform the design of drugs to assist/avoid penile erection.
Ligand design for alpha1 adrenoceptor subtype selective antagonists.[Pubmed:10968279]
Bioorg Med Chem. 2000 Jan;8(1):201-14.
Alpha1 adrenoceptors have three subtypes and drugs interacting selectively with these subtypes could be useful in the treatment of a variety of diseases. In order to gain an insight into the structural principles governing subtype selectivity, ligand based drug design (pharmacophore development) methods have been used to design a novel 1,2,3-thiadiazole ring D analogue of the aporphine system. Synthesis and testing of this compound as a ligand on cloned and expressed human alpha1 adrenoceptors is described. Low binding affinity was found, possibly due to an unfavourable electrostatic potential distribution. Pharmacophore models for antagonists at the three adrenoceptor sites (alpha1A, alpha1B, alpha1D) were generated from a number of different training sets and their value for the design of new selective antagonists discussed. The first preliminary antagonist pharmacophore model for the alpha1D adrenoceptor subtype is also reported.
Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II.[Pubmed:9190864]
J Pharmacol Exp Ther. 1997 Jun;281(3):1284-93.
The aim of the present work was to investigate whether or not the uroselectivity of Rec 15/2739 and several other alpha-1 adrenoceptor (alpha1-AR) antagonists observed in the anesthetized dog could be related to selectivity of these compounds for a particular alpha-1 AR subtype. The binding affinity of the tested compounds for canine prostate alpha-1 ARs and their in vitro functional affinity for the alpha-1 ARs of rabbit urethra and prostate correlated with their functional affinity for the alpha-1L AR subtype, but not with the binding affinity for recombinant animal and human alpha-1a, alpha-1b and alpha-1d AR subtypes. Similar results were obtained when the in vivo potency on urethral pressure was correlated with the affinity for the alpha-1 AR subtypes; also in this case alpha-1L AR gave the best correlation. No correlation was obtained by considering the other alpha-1 AR subtypes. The in vivo hypotensive effects observed in dog after i.v. administration of the considered compounds correlated only with the binding affinity for the animal and human alpha-1d subtype. In conclusion, the results shown in the present paper indicate that the potencies of different alpha-1 antagonists against the contractions induced by norepinephrine on tissues of the lower urinary tract of rabbits and dogs are better correlated with their affinity for the putative alpha-1L subtype than for the alpha-1a subtype. Only the compounds showing selectivity for the alpha-1L subtype versus the alpha-1d subtype proved highly selective in vivo for the lower urinary tract versus the vascular tissues.